Return Home

IA2030 Scorecard — 

Global View

SP 6: Supply & Sustainability
6.1

Healthy global markets for vaccines

What Does this Indicator Measure?

The overall health of a vaccine market includes an assessment of the total number of suppliers, relative concentration among them, ability to distribute globally and the state of the development to quantify whether the market is healthy, concerning, or unhealthy. Measured globally, this indicator assesses the health of 12 vaccine markets.

How Will Progress be Measured?

Regular semi-quantitative assessments of individual market health will be conducted by partners on an annual basis to track level of market health over time, disaggregated by antigen and country typology (e.g., income level).

Level of health of the vaccine market—Global

Vaccine2019/2020
Bacille Calmette-Guerin (BCG)
Unhealthy1
Human papillomavirus (HPV)
Unhealthy
Pneumococcal conjugate vaccine (PCV)
Concerning2
Pneumococcal polysaccharide
Concerning2
Measles
Concerning3
Measles-rubella
Concerning3
Measles-mumps-rubella (MMR)
Concerning3
Penta (whole-cell pertussis-containing)
Healthy4
Hexa (acellular pertussis-containing)
Unhealthy4
Tetanus-diphtheria
Healthy4
Inactivated polio vaccine, stand-alone
Healthy5
Rotavirus
Healthy6

1) No market study update in 2020 - same as 2019.

2) Unavailable as MI4A pneumococcal market study not yet completed.

3) Unavailable as MI4A measles market study not yet completed.

4) No market study update - same as 2019.

5) Same as 2019.

6) Unavailable as UNICEF SD market note not yet completed.

Definition: Level of health of the market, disaggregated by antigen and country typology (Gavi, non-Gavi middle-income countries, high-income countries).
Measurement approach: A number of criteria have been defined to determine the level of health of a market. The number of criteria 'met' directly determines the health of the market for each vaccine. The overall health of a vaccine market includes an assessment of the total number of suppliers, relative concentration among them, ability to distribute globally and the state of the development pipeline. The total numbers of suppliers making a specific vaccine give only a partial picture; the market share of the two largest producers provides a sense of how balanced the market is between different suppliers while reach indicates how many vaccines are truly available globally. Lastly, the "innovation" heading indicates the number of vaccines in late-stage development. Markets with a small number of current global producers but with multiple products in the pipeline are viewed as healthier than those with fewer products in the pipeline.
Calculation: Based on assessments of individual antigens and a holistic overview of each market's programmatic context, a semi-quantitative review of the individual market health will be conducted by partners such as WHO, UNICEF, Gavi, and the Bill & Melinda Gates Foundation.

The IA2030 Scorecard visualizes the monitoring and evaluation indicators of the IA2030 Framework for Action endorsed in 2020 by the World Health Assembly, with the support of countries and partners. The scorecard is a collaborative effort led by MOMENTUM Country and Global Leadership working in partnership with the IA2030 Working Groups on Monitoring & Evaluation and Communications & Advocacy, with oversight from the IA2030 Secretariat and Coordinating Committee. Share feedback here.

This resource is freely available for use per the Creative Commons license: Attribution 4.0 International.


Citation: Immunization Agenda (IA2030) Scorecard. scorecard.immunizationagenda2030.org.